Erasca

ERASNASDAQ

RAS pathway-focused precision oncology platform

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.

text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from

oncologyprecision medicine

Key figures from SEC filings

We have not parsed a 10-Q or 10-K for ERAS yet, so this page shows no cash, burn or runway figure rather than an estimate. Revenue stage: Pre-revenue.

Upcoming catalysts

Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.

SEACRAFT-2: Naporafenib + trametinib in NRAS-mutant cutaneous melanoma — primary completion

2028-04

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

Pipeline

DrugIndicationPhaseExpected data
NaporafenibNRAS-mutant melanomaPhase 3Not disclosed▼
ERAS-007RAS/MAPK-driven solid tumorsPhase 1Not disclosed▼
ERAS-601solid tumorsPhase 1Not disclosed▼

Analysis

We have not yet written an analysis of Erasca that is specific and current enough to publish. Earlier text here was removed rather than left up: on most profiles it was a template shared with other companies, and where a correction is listed above, it was written before the facts changed. The filing figures, pipeline and sourced catalysts on this page are current; the written thesis will be added from them.
Trade ERAS commission-free on Webullvia Webull · Affiliate

Comparable companies

Revolution MedicinesMirati TherapeuticsRelay Therapeutics

Sponsored

Get premium ERAS analysis on Seeking Alpha

Affiliate link — we may earn a commission at no cost to you

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

Erasca has 4 Phase 2 or 3 studies on ClinicalTrials.gov: 2 completed, 1 stopped early, 1 ongoing.

2

Completed

1

Stopped early

1

Ongoing

Stopped early

  • HERKULES-4Phase 1/2 · started 2022 · withdrawn

    ERAS-007 in acute myeloid leukemia · n=0

    Reason given: Sponsor decision.

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.